Antidepressants are looking to be big-time recession-busters. In spite of the cost of brand-name meds, Eli Lilly's Cymbalta has grown by leaps and bounds during the economic downturn, with second-quarter sales up by 14 percent year-over-year. And antidepressants in general haven't halted their upward trend, posting $9.6 billion in 2008 sales, up from $9.4 billion in 2007, on 164 million scrips, up from 160 million. Report [1]